VNDA (Vanda Pharmaceuticals) Debt-to-Equity : 0.02 (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Debt-to-Equity?

Vanda Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $4.3 Mil. Vanda Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $8.1 Mil. Vanda Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $538.5 Mil. Vanda Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vanda Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

VNDA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.02 Max: 0.04
Current: 0.02

During the past 13 years, the highest Debt-to-Equity Ratio of Vanda Pharmaceuticals was 0.04. The lowest was 0.02. And the median was 0.02.

VNDA's Debt-to-Equity is ranked better than
89.95% of 1015 companies
in the Biotechnology industry
Industry Median: 0.14 vs VNDA: 0.02

Vanda Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Vanda Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Debt-to-Equity Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.02

Vanda Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.02	0.02	0.02	0.02

Competitive Comparison of Vanda Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Vanda Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vanda Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Vanda Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vanda Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.27	+	8.09)	/	538.546
	=	0.02

Vanda Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.27	+	8.09)	/	538.546
	=	0.02

Vanda Pharmaceuticals (NAS:VNDA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vanda Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0LKB:UK VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Executives

Mihael Hristos Polymeropoulos	director, officer: Chief Executive Officer	9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Kevin Patrick Moran	officer: VP, Acting CFO & Treasurer	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Stephen Ray Mitchell	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Timothy Williams	officer: SVP & General Counsel	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Joakim Wijkstrom	officer: SVP, Chief Marketing Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Gunther Birznieks	officer: SVP, Business Development	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins	director	1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones	officer: Chief Corp. Affairs Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos	director	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan	director	20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly	officer: SVP, CFO, Treasurer & Secretar	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi	officer: SVP, General Manager Europe	2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341